A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

163

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

February 29, 2008

Study Completion Date

February 29, 2008

Conditions
Obesity
Interventions
DRUG

exenatide

subcutaneous injection (5mcg or 10mcg), twice a day

DRUG

placebo

subcutaneous injection (equivalent volume to active dose), twice a day

Trial Locations (16)

Unknown

Research Site, Peoria

Research Site, Tucson

Research Site, Santa Ana

Research Site, Indianapolis

Research Site, Topeka

Research Site, Wichita

Research Site, Baton Rouge

Research Site, St Louis

Research Site, Oklahoma City

Research Site, Goose Creek

Research Site, Spartanburg

Research Site, Dallas

Research Site, San Antonio

Research Site, Renton

Research Site, Ponce

Research Site, San Juan

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

AstraZeneca

INDUSTRY

NCT00500370 - A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients | Biotech Hunter | Biotech Hunter